PT  - JOURNAL ARTICLE
AU  - Agus Hasan
AU  - Hadi Susanto
AU  - Muhammad Firmansyah Kasim
AU  - Nuning Nuraini
AU  - Bony Lestari
AU  - Dessy Triany
AU  - Widyastuti Widyastuti
TI  - Superspreading in Early Transmissions of COVID-19 in Indonesia
AID  - 10.1101/2020.06.28.20142133
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.06.28.20142133
4099  - http://medrxiv.org/content/early/2020/07/24/2020.06.28.20142133.short
4100  - http://medrxiv.org/content/early/2020/07/24/2020.06.28.20142133.full
AB  - We estimate the basic reproduction number ℛ0 and the overdispersion parameter 𝒦 at two regions in Indonesia: Jakarta-Depok and Batam. Based on the first 1288 confirmed cases in both regions, we find a high degree of individual-level variation in the transmission. The basic reproduction number ℛ0 is estimated at 6.79 and 2.47, while the overdispersion parameter 𝒦 of a negative-binomial distribution is estimated at 0.06 and 0.2 for Jakarta-Depok and Batam, respectively. This suggests that superspreading events played a key role in the early stage of the outbreak, i.e., a small number of infected individuals are responsible for large amounts of COVID-19 transmission.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external finding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not applicable.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available in the manuscript.